Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a publicly traded Healthcare sector company. As of May 21, 2026, MDGL trades at $513.47 with a market cap of $12.04B and a P/E ratio of -39.89. MDGL moved +0.31% today. Year to date, MDGL is -12.73%; over the trailing twelve months it is +75.39%. Its 52-week range spans $200.63 to $615.00. Analyst consensus is strong buy with an average price target of $674.25. Rallies surfaces MDGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes MDGL SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $513.47 |
| Market Cap | $12.04B |
| P/E Ratio | -39.89 |
| EPS | $-12.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $615.00 |
| 52-Week Low | $200.63 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $958.40M |
| Net Income | $-288.28M |
| Gross Margin | 0.00% |
8 analysts cover MDGL: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $674.25.